CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer

Prostate

Volumn 70, Issue 1, 2010, Pages 48-60

  Li, YouQiang ^a   Mizokami, Atsushi ^a   Izumi, Kouji ^a   Narimoto, Kazutaka ^a   Shima, Takashi ^a   Zhang, Jian ^b   Dai, Jinlu ^c   Keller, Evan T ^c   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

CTEN; Gleason score; Paclitaxel sensitivity; Prostate cancer

Indexed keywords

CISPLATIN; CYTOSKELETON PROTEIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; F ACTIN; FOCAL ADHESION KINASE; PACLITAXEL; TENSIN 4; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLEASON SCORE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN LOCALIZATION; RNA INTERFERENCE; TISSUE MICROARRAY;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROFILAMENT PROTEINS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 72849125104     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21037     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: Cancer J Clin 2008;58(2):71-96.
2. Gopalkrishnan RV, Kang DC, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 2001;189(3):245-256. (Pubitemid 33063292)
3. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001;15(3):525-545.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15):1513-1520.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512. (Pubitemid 39315317)
6. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy- Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(15):3343-3351. (Pubitemid 46243478)
7. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17(3):1061-1070. (Pubitemid 29109340)
8. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000;16:89-111.
9. Fojo T, Menefee M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 2007;18(Suppl 5):v3-v8.
10. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 2008;14(9):939-948.
11. Goto T, Takano M, Hirata J, Tsuda H. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br J Cancer 2008;98(6):1068-1075.
12. Mortenson MM, Galante JG, Gilad O, Schlieman MG, Virudachalam S, Kung HJ, Bold RJ. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007;102(5):1171-1179. (Pubitemid 350220038)
13. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007;67(9):955-967. (Pubitemid 46828929)
14. Lo SH, Lo TB. Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Res 2002;62(15):4217-4221.
15. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64(2):765-771. (Pubitemid 38120921)
16. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26 (5 Suppl 17):3-7. (Pubitemid 30000737)
17. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005; 11(4):1572-1578. (Pubitemid 40315242)
18. Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 2006;72(8):941-948. (Pubitemid 44376781)
19. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B, Wan Y. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 2005; 27(5):1441-1448.
20. Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K, Sato Y. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006;97(10):1115-1124. (Pubitemid 44322563)
21. Lo SH, Janmey PA, Hartwig JH, Chen LB. Interactions of tensin with actin and identification of its three distinct actin-binding domains. J Cell Biol 1994;125(5):1067-1075.
22. Davis S, Lu ML, Lo SH, Lin S, Butler JA, Druker BJ, Roberts TM, An Q, Chen LB. Presence of an SH2 domain in the actin-binding protein tensin. Science (New York, NY) 1991;252(5006):712-715.
23. Cui Y, Liao YC, Lo SH. Epidermal growth factor modulates tyrosine phosphorylation of a novel tensin family member, tensin3. Mol Cancer Res 2004;2(4):225-232. (Pubitemid 39031083)
24. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006;146(2):344-353. (Pubitemid 44581351)
25. Vignjevic D, Montagnac G. Reorganisation of the dendritic actin network during cancer cell migration and invasion. Semin Cancer Biol 2008;18(1):12-22.
26. Vicente-Manzanares M, Sanchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat Rev 2004;4(2):110-122.
27. Shih YL, Rothfield L. The bacterial cytoskeleton. Microbiol Mol Biol Rev 2006;70(3):729-754.
28. Herrmann H, Aebi U. Intermediate filament assembly: Fibrillo-genesis is driven by decisive dimer-dimer interactions. Curr Opin Struct Biol 1998;8(2):177-185. (Pubitemid 28221048)
29. Kamal A, Goldstein LS. Connecting vesicle transport to the cytoskeleton. Curr Opin Cell Biology 2000;12(4):503-508.
30. Lo SH, Weisberg E, Chen LB. Tensin: A potential link between the cytoskeleton and signal transduction. Bioessays 1994;16(11): 817-823. (Pubitemid 2161443)
31. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer (Amsterdam, Netherlands) 2005;49(3):337-343. (Pubitemid 41139146)
32. Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 2006;71(6):751-760. (Pubitemid 43208831)
33. Liao YC, Chen NT, Shih YP, Dong Y, Lo SH. Up-regulation of C-terminal tensin-like molecule promotes the tumorigenicity of colon cancer through beta-catenin. Cancer Res 2009;69(11):4563-4566.
34. Sasaki H, Moriyama S, Mizuno K, Yukiue H, Konishi A, Yano M, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Cten mRNA expression was correlated with tumor progression in lung cancers. Lung Cancer (Amsterdam, Netherlands) 2003;40(2): 151-155. (Pubitemid 36438715)
35. Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT, Honn KV. Localization of potential tumor suppressor loci to a <2Mb region on chromosome 17q in human prostate cancer. Oncogene 1995;11(7):1241-1247.
36. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr LR, Brothman AR. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 1996;155(2):720-725. (Pubitemid 26023591)